Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00044694 · ClinicalTrials.gov registry record · Phase 2
Evaluation of the Effect on Glucose Control and the Safety and Tolerability of AC2993 in Patients With Type 2 Diabetes Mellitus
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 156
- Enrollment target
NCT00044694: Completed Phase 2 study, sponsored by AstraZeneca.
NCT00044694 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 156 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (17% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00044694, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 156 participants
- Enrollment target
Study Summary
This is a multicenter, randomized, blinded, placebo-controlled, short-term, dose-response study to examine the effects on glucose control of AC2993 as compared to placebo in patients with type 2 diabetes. Patients will be individuals with type 2 diabetes treated with metformin for at least 3 months prior to screening. Patients whose diabetes management consists of diet and exercise will also be eligible for this study.
Primary Outcome
Change in HbA1c from Baseline (Day 1) to study termination (Day 28)
Interventions
- DRUG Placebo 0.01 mL
- DRUG Placebo 0.02 mL
- DRUG Placebo 0.03 mL
- DRUG Placebo 0.04 mL
- DRUG AC2993 2.5 mcg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 156 participants |
| Start Date | 2002-08 |
| Est. Completion | 2003-05 |
| Phase | Phase 2 |
What the finished NCT00044694 record still lists
NCT00044694 is an interventional study that assigns participants to a tested intervention. The registered 156 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (17% higher).
The record links to 0 conditions, and to 5 interventions - of which Placebo 0.01 mL is the first listed.
NCT00044694 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00044694 about?
NCT00044694 is a clinical study titled "Evaluation of the Effect on Glucose Control and the Safety and Tolerability of AC2993 in Patients With Type 2 Diabetes Mellitus". This is a multicenter, randomized, blinded, placebo-controlled, short-term, dose-response study to examine the effects on glucose control of AC2993 as compared to placebo in patients with type 2 diabetes. Patients will be individuals with type 2 diabetes treated with metformin for at least 3 months ...
What is the current status of trial NCT00044694?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 156 participants. The study started on 2002-08. Estimated completion is 2003-05.
What interventions are being tested in trial NCT00044694?
The interventions under investigation include: Placebo 0.01 mL (DRUG), Placebo 0.02 mL (DRUG), Placebo 0.03 mL (DRUG), Placebo 0.04 mL (DRUG), AC2993 2.5 mcg (DRUG).
Who is sponsoring clinical trial NCT00044694?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00044694's enrollment target sits among peer trials
156 445th of 2000 higher than 1,553 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03082755 · 156 participants · Phase 4
Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease
- NCT04047628 · 156 participants · Phase 3
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
- NCT04166877 · 156 participants · Phase 4
Magnesium Infusion for Pain Management in Critically Ill Trauma Patients
- NCT04533464 · 156 participants · Phase 2
MultiStem® for Treatment of Trauma Induced Multiple Organ Failure/Systemic Inflammatory Response Syndrome
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia